Evaluation of health-related quality of life in gastroesophageal reflux disease patients before and after treatment with pantoprazole

Diseases of the Esophagus

Volumn 19, Issue 4, 2006, Pages 289-293

  de Souza Cury, M ^a   Ferrari, A P ^a   Ciconelli, R ^a   Ferraz, M B ^a   Moraes Filho, Joaquim Prado P ^b,c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c NONE   (Brazil)

Author keywords

Gastroesophageal reflux; Heartburn; Pantoprazole; Quality of life

Indexed keywords

PANTOPRAZOLE;

ADULT; ARTICLE; BRAZIL; CLINICAL PROTOCOL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; ENDOSCOPY; ESOPHAGITIS; EVALUATION; FEMALE; GASTROESOPHAGEAL REFLUX; HEALING; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; SCORING SYSTEM; SHORT FORM 36; STATISTICAL ANALYSIS; VALIDATION PROCESS; VALIDITY; WESTERN HEMISPHERE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; ANTI-ULCER AGENTS; BRAZIL; ENDOSCOPY, DIGESTIVE SYSTEM; ESOPHAGITIS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SICKNESS IMPACT PROFILE; TRANSLATING;

EID: 33745833346     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2006.00581.x     Document Type: Article

References (34)

1. Eisen G. The epidemiology of gastroesophageal reflux disease: What we know and what we need to know. Am J Gastroenterol 2001; 96: S16-18.
2. Locke G R 3rd, Talley N J, Fett S L, Zinsmeister A R, Melton L J 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County. Minnesota Gastroenterol 1997; 112: 1448-56.
3. Spechler S J. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51: 24-9.
4. Frank L, Kleinman L, Ganoczy D et al. Upper gastrointestinal symptoms in North America: Prevalence and relationship to healthcare utilization and quality of life. Dig Dis Sci 2000; 45: 809-18.
5. Moraes-Filho J P P, Chinzon D, Eisig J et al. Prevalence of heartburn and gastroesophageal reflux disease in the urban Brazilian population. Arq Gastroenterol 2005; 42: 122-7.
6. Borgaonkar M R, Irvine E J. Quality of life measurement in gastrointestinal and liver disorders. Gut 2000; 47: 444-54.
7. Eisen G M, Locke G R 3rd, Provenzale D. Health-related quality of life: a primer for gastroenterologists. Am J Gastroenterol 1999; 94: 2017-21.
8. Guillemin F. Functional disability and quality-of-life assessment in clinical practice. Rheumatology (Oxford) 2000; 39: 17-23.
9. McDougall N I, Collins J S, McFarland R J, Watson R G, Love A H. The effect of treating reflux oesophagitis with omeprazole on quality of life [see comments]. Eur J Gastroenterol Hepatol 1998; 10: 459-64.
10. Revicki D A, Wood M, Maton P N, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998; 104: 252-8.
11. Revicki D A, Crawley J A, Zodet M W, Levine D S, Joelsson B O. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 1621-30.
12. Granderath F A, Kamolz T, Schweiger U M, Pasiut M, Wykypiel H Jr, Pointner R. Quality of life and symptomatic outcome three to five years after laparoscopic Toupet fundoplication in gastroesophageal reflux disease patients with impaired esophageal motility. Am J Surg 2002; 183: 110-16.
13. Slim K, Bousquet J, Kwiatkowski F, Lescure G, Pezet D, Chipponi J. Quality of life before and after laparoscopic fundoplication. Am J Surg 2000; 180: 41-5.
14. Triadafilopoulos G, DiBaise J K, Nostrant T T et al. The Stretta procedure for the treatment of GERD: 6 and 12 month follow- up of the U.S. open label trial. Gastrointest Endosc 2002; 55: 149-56.
15. Freston J W, Triadafilopoulos G. Approaches to the long-term management of adults with GERD-proton pump inhibitor therapy, laparoscopic fundoplication or endoscopic therapy? Aliment Pharmacol Ther 2004; 19: 35-42.
16. Heikkinen T J, Haukipuro K, Bringman S, Ramel S, Sorasto A, Hulkko A. Comparison of laparoscopic and open Nissen fundoplication 2 years after operation. A prospective randomized trial. Surg Endosc 2000; 14: 1019-23.
17. Stanghellini V, Armstrong D, Monnikes H, Bardhan K D. Do we need a new gastro-oesophageal reflux disease questionnaire? Aliment Pharmacol Ther 2004; 19: 463-79.
18. Wiklund I, Bardhan K D, Muller-Lissner S et al. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group. Ital J Gastroenterol Hepatol 1998; 30: 19-27.
19. Allen C J, Parameswaran K, Belda J, Anvari M. Reproducibility, validity, and responsiveness of a disease-specific symptom questionnaire for gastroesophageal reflux disease. Dis Esophagus 2000; 13: 265-70.
20. Lundell L R, Dent J, Bennett J R et al. Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80.
21. Moraes-Filho J P P, Cecconello I, Gama-Rodrigues J et al. Brazilian Consensus on Gastroesophageal Reflux Disease: Proposals for Assesment, Classification, and Management. Am J Gastroenterol 2002; 97: 241-8.
22. Klauser A G, Schindlbeck N E, Muller-Lissner S A. Symptoms in gastro-oesophageal reflux disease. Lancet 1990; 335: 205-8.
23. Ciconelli R M, Ferraz M B, Santos W, Meinão I, Quaresma M R. Tradução para a lingua portuguesa e validação do questionário genérico de avaliação de qualidade de vida SF-36 (Brasil SF-36). Rev Bras Reumatol 1999; 39: 143-50.
24. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: Literature review and proposed guidelines. J Clin Epidemiol 1993; 46: 1417-32.
25. Guillemin F. Cross-cultural adaptation and validation of health status measures. Scand J Rheumatol 1995; 24: 61-3.
26. Glise H. Quality of life and cost of therapy in reflux disease. Scand J Gastroenterol Suppl 1995; 210: 38-42.
27. Kaspari S, Biedermann A, Mey J. Comparison of pantoprazole 20 mg to ranitidine 150 mg b.i.d. in the treatment of mild gastroesophageal reflux disease. Digestion 2001; 63: 163-70.
28. Kulig M, Leodolter A, Vieth M et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease - an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003; 18: 767-76.
29. Ofman J J. The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98: S8-S14.
30. Stanghellini V, Cogliandro R, Cogliandro L, De Giorgio R, Barbara G, Corinaldesi R. Unsolved problems in the management of patients with gastro-oesophageal reflux disease. Dig Liver Dis 2003; 35: 843-8.
31. Nunnaly J C, Berstein I H. Psychometric Theory, 3rd edn. New York: Mc Graw-Hill College 1994, 182-9.
32. Senna E R. Estudo sobre prevalência de doenças reumáticas na cidade de Montes Claros [Doutorado]. São Paulo: UNIFESP 2002.
33. Stanghellini V. Relationship between upper gastrointestinal symptoms and lifestyle, psychosocial factors and comorbidity in the general population: Results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999; 231: 29-37.
34. Moraes-Filho J P P. Doenças funcionais do aparelho digestivo: A importância dos distúrbios emocionais na gênese dos sintomas. Rev Bras Med 1994; 51: 1395-401.